|
Volumn 35, Issue 5, 2000, Pages 811-812
|
Letter to the editor [6] (multiple letters)
a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
DOXORUBICIN;
THYROID TRANSCRIPTION FACTOR 1;
ANTINEOPLASTIC AGENT;
BIOLOGICAL MARKER;
NUCLEAR PROTEIN;
THYROID NUCLEAR FACTOR 1;
TRANSCRIPTION FACTOR;
ARTICLE;
CELL MIGRATION;
ESOPHAGUS;
ESOPHAGUS ATRESIA;
GASTROESOPHAGEAL REFLUX;
HUMAN;
INNERVATION;
NERVE CELL;
PHYSICAL DEVELOPMENT;
PRIORITY JOURNAL;
TRACHEOESOPHAGEAL FISTULA;
ANIMAL;
BIOSYNTHESIS;
CHEMICALLY INDUCED DISORDER;
CONGENITAL MALFORMATION;
DISEASE MODEL;
METABOLISM;
NOTE;
PRENATAL DEVELOPMENT;
RAT;
SENSITIVITY AND SPECIFICITY;
TRACHEA;
ANIMALS;
ANTINEOPLASTIC AGENTS;
BIOLOGICAL MARKERS;
DISEASE MODELS, ANIMAL;
DOXORUBICIN;
ESOPHAGUS;
NUCLEAR PROTEINS;
RATS;
SENSITIVITY AND SPECIFICITY;
TRACHEA;
TRACHEOESOPHAGEAL FISTULA;
TRANSCRIPTION FACTORS;
|
EID: 0034182056
PISSN: 00223468
EISSN: None
Source Type: Journal
DOI: 10.1016/s0022-3468(00)70013-3 Document Type: Article |
Times cited : (3)
|
References (4)
|